November 14, 2024
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…
Pharmaceuticals, Biotechnology and Life Sciences
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…
Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo,…
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) — In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:…
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova…
HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its…
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new “gold standard” outperforming…
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”),…
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov.…
LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…
HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its…